Hologic (NASDAQ:HOLX) had its price target cut by ISI Group from $26.00 to $25.00 in a research note issued to investors on Tuesday, Analyst Ratings Network reports. The firm currently has a strong-buy rating on the stock.
In other Hologic news, CFO Glenn P. Muir unloaded 140,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $22.32, for a total value of $3,124,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Hologic (NASDAQ:HOLX) traded up 0.39% during mid-day trading on Tuesday, hitting $20.59. 7,902,617 shares of the company’s stock traded hands. Hologic has a 52 week low of $18.46 and a 52 week high of $23.96. The stock’s 50-day moving average is $21.71 and its 200-day moving average is $21.21. The company’s market cap is $5.568 billion. Hologic also was the target of some unusual options trading on Tuesday. Investors acquired 6,011 put options on the stock. This is an increase of 698% compared to the typical volume of 753 put options.
Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 11th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.02. The company had revenue of $622.10 million for the quarter, compared to the consensus estimate of $624.40 million. During the same quarter in the previous year, the company posted $0.37 earnings per share. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, analysts predict that Hologic will post $1.44 earnings per share for the current fiscal year.
HOLX has been the subject of a number of other recent research reports. Analysts at Cantor Fitzgerald cut their price target on shares of Hologic from $21.00 to $19.00 in a research note to investors on Tuesday. They now have a hold rating on the stock. Separately, analysts at Citigroup Inc. reiterated a neutral rating on shares of Hologic in a research note to investors on Tuesday. They now have a $22.00 price target on the stock, down previously from $24.00. Finally, analysts at SunTrust reiterated a reduce rating on shares of Hologic in a research note to investors on Tuesday. They now have a $15.00 price target on the stock, down previously from $17.00. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Hologic has an average rating of Hold and a consensus target price of $22.00.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.